Table 1.
Patient demographics
| n = 24 (%) whole cohort | n = 13 (%) cohort with endoscopic follow-up |
|
|---|---|---|
| Female | 10 (42) | 5 (38) |
| Median age at first ustekinumab dose (IQR) | 35.6 (26.6–41.5) | 31.1 (27.4–39.3) |
| Smoking status | ||
| Current smoker | 1 (4.2) | 1 (8) |
| Ex-smoker | 2 (8.3) | 0 (0) |
| Never | 21 (87.5) | 12 (92) |
| Median BMI (IQR) | 24.4 (23–27) | 25 (23–27) |
| PSC | 2 (8.3) | 2 (15) |
| Caucasian | 20 (83) | 11 (85) |
| Extensive colitis prior to colectomy | 21 (87.5) | 12 (92) |
| Treatment prior to colectomy | ||
| Mesalamine | 12 (50) | 7 (54) |
| Immunomodulator | 16 (66.7) | 11 (85) |
| Azathioprine | 15 (62.5) | 10 (77) |
| MTX | 1(4.2) | 1(8) |
| Biologics | 14(58.3) | 8(62) |
| Infliximab | 14 (58.3) | 8 (62) |
| Adalimumab | 2 (8.3) | 1 (8) |
| Vedolizumab | 1 (4.2) | 0 (0) |
| Antibiotics | 35 (21.3) | 3 (23) |
| Prednisone | 13 (54.1) | 8 (62) |
| Treatment after colectomy | ||
| Mesalamine | 6 (25) | 3 (23) |
| Immunomodulator | 6 (25) | 4 (31) |
| Azathioprine | 6 (25) | 4(31) |
| Biologics | 12 (50) | 6 (46) |
| Infliximab | 6 (25) | 3 (23) |
| Adalimumab | 9 (37.5) | 4 (31) |
| Vedolizumab | 4 (16.7) | 3 (23) |
| Certolizumab pegol | 3 (12.5) | 2 (15) |
| Antibiotics | 24 (100) | 13 (100) |
| Prednisone | 13 (54.2) | 9 (69) |
| Budesonide | 16 (66.7) | 8 (62) |
| Rifaximine | 2 (8.3) | 2 (15) |
| VSL | 6 (25) | 1 (8) |
| Biologic naïve prior to UST infusion | 4 (16) | 3 (23) |
| Median PDAI prior to UST infusion | 5(3–6) | 5 (4–6) |
| Median follow-up period—months (IQR) | 12.6 (5.2–10.76) | 16.9 (15–18.7) |